A detailed history of Jacobs Levy Equity Management, Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 2,793,204 shares of NKTR stock, worth $3.27 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,793,204
Previous 2,873,192 2.78%
Holding current value
$3.27 Million
Previous $3.56 Million 1.94%
% of portfolio
0.01%
Previous 0.02%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.11 - $1.48 $88,786 - $118,382
-79,988 Reduced 2.78%
2,793,204 $3.63 Million
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $865,805 - $1.76 Million
962,006 Added 50.34%
2,873,192 $3.56 Million
Q1 2024

May 15, 2024

SELL
$0.49 - $0.96 $731,559 - $1.43 Million
-1,492,979 Reduced 43.86%
1,911,186 $1.78 Million
Q4 2023

Feb 14, 2024

SELL
$0.42 - $0.57 $630,243 - $855,330
-1,500,580 Reduced 30.59%
3,404,165 $1.91 Million
Q3 2023

Nov 16, 2023

BUY
$0.51 - $1.05 $17,476 - $35,980
34,267 Added 0.7%
4,904,745 $2.94 Million
Q2 2023

Aug 14, 2023

BUY
$0.53 - $1.03 $1.19 Million - $2.32 Million
2,252,391 Added 86.03%
4,870,478 $2.82 Million
Q1 2023

May 15, 2023

BUY
$0.64 - $3.15 $30,232 - $148,799
47,238 Added 1.84%
2,618,087 $1.83 Million
Q4 2022

Feb 14, 2023

BUY
$2.03 - $4.28 $3.11 Million - $6.56 Million
1,532,920 Added 147.69%
2,570,849 $5.81 Million
Q3 2022

Nov 15, 2022

BUY
$3.04 - $5.14 $2.46 Million - $4.16 Million
809,966 Added 355.31%
1,037,929 $3.32 Million
Q2 2022

Aug 15, 2022

BUY
$3.17 - $6.17 $722,642 - $1.41 Million
227,963 New
227,963 $866,000
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $386,534 - $1.27 Million
-92,917 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $63,193 - $107,422
5,835 Added 6.7%
92,917 $1.26 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $805,125 - $1.16 Million
61,601 Added 241.75%
87,082 $1.56 Million
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $97,038 - $119,829
5,874 Added 29.96%
25,481 $437,000
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $925,190 - $1.42 Million
-55,869 Reduced 74.02%
19,607 $392,000
Q4 2020

Feb 16, 2021

SELL
$15.77 - $19.03 $20,579 - $24,834
-1,305 Reduced 1.7%
75,476 $1.28 Million
Q3 2020

Nov 16, 2020

BUY
$16.59 - $24.79 $302,867 - $452,566
18,256 Added 31.19%
76,781 $1.27 Million
Q2 2020

Aug 17, 2020

BUY
$16.86 - $23.44 $986,731 - $1.37 Million
58,525 New
58,525 $1.36 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.